Literature DB >> 22892726

Polyglutamine (polyQ) disorders: the chromatin connection.

Dorit Cohen-Carmon1, Eran Meshorer.   

Abstract

Polyglutamine (PolyQ)-related diseases are dominant late-onset genetic disorders that are manifested by progressive neurodegeneration, leading to behavioral and physical impairments. An increased body of evidence suggests that chromatin structure and epigenetic regulation are involved in disease pathology. PolyQ diseases often display an aberrant transcriptional regulation due to the disrupted function of histone-modifying complexes and altered interactions of the polyQ-extended proteins with chromatin-related factors. In this review we describe recent findings relating to the role of chromatin in polyQ diseases. We discuss the involvement of epigenetic-related factors and chromatin structure in genomic instability of CAG repeats; we describe changes in the expression and regulation of chromatin-related enzymes and in the levels and patterns of histone modifications in disease state; we illustrate the potential beneficial effects of different histone deacetylase (HDAC) inhibitors for the treatment of polyQ diseases, and we end by describing the potential use of human pluripotent stem cells and their differentiated derivatives for modeling polyQ diseases in vitro. Taken together, these accumulating studies strongly suggest that disrupted chromatin regulation may be directly involved with the pathophysiology of polyQ-related diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892726      PMCID: PMC3474664          DOI: 10.4161/nucl.21481

Source DB:  PubMed          Journal:  Nucleus        ISSN: 1949-1034            Impact factor:   4.197


  96 in total

1.  Gcn5 loss-of-function accelerates cerebellar and retinal degeneration in a SCA7 mouse model.

Authors:  Yi Chun Chen; Jennifer R Gatchel; Rebecca W Lewis; Chai-An Mao; Patrick A Grant; Huda Y Zoghbi; Sharon Y R Dent
Journal:  Hum Mol Genet       Date:  2011-10-14       Impact factor: 6.150

2.  MicroRNA-mediated conversion of human fibroblasts to neurons.

Authors:  Andrew S Yoo; Alfred X Sun; Li Li; Aleksandr Shcheglovitov; Thomas Portmann; Yulong Li; Chris Lee-Messer; Ricardo E Dolmetsch; Richard W Tsien; Gerald R Crabtree
Journal:  Nature       Date:  2011-07-13       Impact factor: 49.962

3.  REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons.

Authors:  J A Chong; J Tapia-Ramírez; S Kim; J J Toledo-Aral; Y Zheng; M C Boutros; Y M Altshuller; M A Frohman; S D Kraner; G Mandel
Journal:  Cell       Date:  1995-03-24       Impact factor: 41.582

4.  Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration.

Authors:  Vikas B Palhan; Shiming Chen; Guang-Hua Peng; Agneta Tjernberg; Armin M Gamper; Yuxin Fan; Brian T Chait; Albert R La Spada; Robert G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

Review 5.  Histone deacetylase inhibitors: Potential in cancer therapy.

Authors:  P A Marks; W-S Xu
Journal:  J Cell Biochem       Date:  2009-07-01       Impact factor: 4.429

6.  Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.

Authors:  Tarja A Juopperi; Woon Ryoung Kim; Cheng-Hsuan Chiang; Huimei Yu; Russell L Margolis; Christopher A Ross; Guo-li Ming; Hongjun Song
Journal:  Mol Brain       Date:  2012-05-21       Impact factor: 4.041

7.  Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.

Authors:  Anna Bobrowska; Paolo Paganetti; Patrick Matthias; Gillian P Bates
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

8.  Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.

Authors:  Stuart M Chambers; Christopher A Fasano; Eirini P Papapetrou; Mark Tomishima; Michel Sadelain; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2009-03-01       Impact factor: 54.908

9.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

10.  Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.

Authors:  Caroline L Benn; Rachel Butler; Lydia Mariner; Jude Nixon; Hilary Moffitt; Michal Mielcarek; Ben Woodman; Gillian P Bates
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

View more
  14 in total

Review 1.  Epigenetic mechanisms of neurodegenerative diseases and acute brain injury.

Authors:  Mario J Bertogliat; Kahlilia C Morris-Blanco; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2019-12-12       Impact factor: 3.921

2.  HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.

Authors:  Haiqun Jia; Charles D Morris; Roy M Williams; Jeanne F Loring; Elizabeth A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 3.  Balancing chromatin remodeling and histone modifications in transcription.

Authors:  Emily Petty; Lorraine Pillus
Journal:  Trends Genet       Date:  2013-07-16       Impact factor: 11.639

4.  A Drosophila model of Huntington disease-like 2 exhibits nuclear toxicity and distinct pathogenic mechanisms from Huntington disease.

Authors:  Megan Krench; Richard W Cho; J Troy Littleton
Journal:  Hum Mol Genet       Date:  2016-06-10       Impact factor: 6.150

5.  Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.

Authors:  Soram Idiyasan Chanu; Surajit Sarkar
Journal:  Mol Neurobiol       Date:  2016-03-21       Impact factor: 5.590

6.  Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.

Authors:  Elizabeth A Thomas
Journal:  Pharmaceuticals (Basel)       Date:  2014-05-26

7.  Statistical Enrichment of Epigenetic States Around Triplet Repeats that Can Undergo Expansions.

Authors:  Alexandra Essebier; Patricia Vera Wolf; Minh Duc Cao; Bernard J Carroll; Sureshkumar Balasubramanian; Mikael Bodén
Journal:  Front Neurosci       Date:  2016-03-08       Impact factor: 4.677

8.  The HDAC interaction network.

Authors:  Ilana Livyatan; Eran Meshorer
Journal:  Mol Syst Biol       Date:  2013       Impact factor: 11.429

Review 9.  From pathways to targets: understanding the mechanisms behind polyglutamine disease.

Authors:  Jonasz Jeremiasz Weber; Anna Sergeevna Sowa; Tina Binder; Jeannette Hübener
Journal:  Biomed Res Int       Date:  2014-09-21       Impact factor: 3.411

Review 10.  Roles of Post-translational Modifications in Spinocerebellar Ataxias.

Authors:  Linlin Wan; Keqin Xu; Zhao Chen; Beisha Tang; Hong Jiang
Journal:  Front Cell Neurosci       Date:  2018-09-19       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.